This website is intended exclusively for healthcare professionals residing and/or working in the KSA.
HomeProductsSarclisa®IKEMA: mPFS of 3 years with SARCLISA + Kd is longest ever reported for anti-CD38 therapy in a pivotal trial that included lenalidomide-refractory patients